Emerging therapies for glycogen storage disease type I

Trends in Endocrinology and Metabolism

Volumn 20, Issue 5, 2009, Pages 252-258

  Koeberl, D D ^a   Kishnani, P S ^a   Bali, D ^a   Chen, Y T ^a,b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CAPTOPRIL; CITRIC ACID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRIC ACID DERIVATIVE; GLUCOSE; GLUCOSE 6 PHOSPHATASE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LISINOPRIL; MESALAZINE; PARVOVIRUS VECTOR; STARCH;

AMYLOIDOSIS; CELL METABOLISM; CLINICAL TRIAL; DIET SUPPLEMENTATION; DIET THERAPY; DRUG EFFICACY; DRUG RESPONSE; GENE MUTATION; GLYCOGEN STORAGE DISEASE TYPE 1; HUMAN; HYPERLIPIDEMIA; INCIDENCE; INFECTION; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; LOW DRUG DOSE; MICROALBUMINURIA; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SURVIVAL RATE; THERAPY EFFECT; THYROID DISEASE; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

GENE THERAPY; GLYCOGEN STORAGE DISEASE TYPE I; HUMANS; MODELS, BIOLOGICAL;

EID: 67649224091     PISSN: 10432760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tem.2009.02.003     Document Type: Review

References (61)

1. Chen Y.-T. Glycogen Storage Diseases. In: Scriver C.R., Beaudet A.L., Sly W.S., and Valle D. (Eds). The Metabolic and Molecular Bases of Inherited Disease (2001), McGraw-Hill, New York 1521-1551
2. Moses S.W. Historical highlights and unsolved problems in glycogen storage disease type 1. Eur. J. Pediatr. 161 suppl. 1 (2002) S2-S9
3. Franco L.M., et al. Hepatocellular carcinoma in glycogen storage disease type Ia: a case series. J. Inherit. Metab. 28 (2005) 153-162
4. Melis D., et al. Increased prevalence of thyroid autoimmunity and hypothyroidism in patients with glycogen storage disease type I. J.Pediatr. 150 (2007) 300-305
5. Chen Y.T., et al. Type I glycogen storage disease: nine years of management with cornstarch. Eur. J. Pediatr. 152 Suppl 1 (1993) S56-S59
6. Bhattacharya K., et al. A novel starch for the treatment of glycogen storage diseases. J. Inherit. Metab. Dis. 30 (2007) 350-357
7. Nagasaka H., et al. Improvements of hypertriglyceridemia and hyperlacticemia in Japanese children with glycogen storage disease type Ia by medium-chain triglyceride milk. Eur. J. Pediatr. 166 (2007) 1009-1016
8. Humbert M., et al. Pulmonary arterial hypertension and type-I glycogen-storage disease: the serotonin hypothesis. Eur. Respir. J. 20 (2002) 59-65
9. Chou J.Y., and Mansfield B.C. Mutations in the glucose-6-phosphatase-alpha (G6PC) gene that cause type Ia glycogen storage disease. Hum. Mutat. 29 (2008) 921-930
10. Matern D., et al. Glycogen storage disease type I: diagnosis and phenotype/genotype correlation. Eur. J. Pediatr. 161 Suppl 1 (2002) S10-S19
11. Shieh J.J., et al. The molecular basis of glycogen storage disease type 1a: structure and function analysis of mutations in glucose-6-phosphatase. J. Biol. Chem. 277 (2002) 5047-5053
12. Yuen Y.P., et al. Novel missense mutation (Y24H) in the G6PT1 gene causing glycogen storage disease type 1b. Mol. Genet. Metab. 77 (2002) 249-251
13. Weston B.W., et al. Glucose-6-phosphatase mutation G188R confers an atypical glycogen storage disease type 1b phenotype. Pediatr. Res. 48 (2000) 329-334
14. Kure S., et al. Glycogen storage disease type Ib without neutropenia. J. Pediatr. 137 (2000) 253-256
15. Kim S.Y., et al. Necrotic foci, elevated chemokines and infiltrating neutrophils in the liver of glycogen storage disease type Ia. J. Hepatol. 48 (2008) 479-485
16. Chen S.Y., et al. The glucose-6-phosphate transporter is a phosphate-linked antiporter deficient in glycogen storage disease type Ib and Ic. FASEB J. 22 (2008) 2206-2213
17. Wang Y., et al. Long-range enhancers are required to maintain expression of the autoantigen islet-specific glucose-6-phosphatase catalytic subunit-related protein in adult mouse islets in vivo. Diabetes 57 (2008) 133-141
18. Wang Y., et al. Deletion of the gene encoding the islet-specific glucose-6-phosphatase catalytic subunit-related protein autoantigen results in a mild metabolic phenotype. Diabetologia 50 (2007) 774-778
19. Bouatia-Naji N., et al. A polymorphism within the G6PC2 gene is associated with fasting plasma glucose levels. Science 320 (2008) 1085-1088
20. Shieh J.J., et al. A glucose-6-phosphate hydrolase, widely expressed outside the liver, can explain age-dependent resolution of hypoglycemia in glycogen storage disease type Ia. J. Biol. Chem. 278 (2003) 47098-47103
21. Wang Y., et al. Deletion of the gene encoding the ubiquitously expressed glucose-6-phosphatase catalytic subunit-related protein (UGRP)/glucose-6-phosphatase catalytic subunit-beta results in lowered plasma cholesterol and elevated glucagon. J. Biol. Chem. 281 (2006) 39982-39989
22. Cheung Y.Y., et al. Impaired neutrophil activity and increased susceptibility to bacterial infection in mice lacking glucose-6-phosphatase-beta. J. Clin. Invest. 117 (2007) 784-793
23. Weinstein D.A., et al. Inappropriate expression of hepcidin is associated with iron refractory anemia: implications for the anemia of chronic disease. Blood 100 (2002) 3776-3781
24. Reddy S.K., et al. Resection of hepatocellular adenoma in patients with glycogen storage disease type Ia. J. Hepatol. 47 (2007) 658-663
25. Semrin G., et al. Impaired intestinal iron absorption in Crohn's disease correlates with disease activity and markers of inflammation. Inflamm. Bowel Dis. 12 (2006) 1101-1106
26. Kim S.Y., et al. Neutrophil stress and apoptosis underlie myeloid dysfunction in glycogen storage disease type Ib. Blood 111 (2008) 5704-5711
27. Mundy H.R., and Lee P.J. Glycogenosis type I and diabetes mellitus: a common mechanism for renal dysfunction?. Med. Hypotheses 59 (2002) 110-114
28. Yiu W.H., et al. Angiotensin mediates renal fibrosis in the nephropathy of glycogen storage disease type Ia. Kidney Int. 73 (2008) 716-723
29. Bandsma R.H., et al. Increased de novo lipogenesis and delayed conversion of large VLDL into IDL particles contribute to hyperlipidemia in glycogen storage disease type 1a. Pediatr. Res. 63 (2008) 702-707
30. Melis D., et al. Efficacy of ACE-inhibitor therapy on renal disease in glycogen storage disease type 1: a multicentre retrospective study. Clin. Endocrinol. (Oxf.) 63 (2005) 19-25
31. Davis, M.K. et al. Adalimumab for the treatment of Crohn-like colitis and enteritis in glycogen storage disease type Ib. J. Inherit. Metab. Dis. (in press)
32. Weinstein D.A., et al. Decreased urinary citrate excretion in type 1a glycogen storage disease. J. Pediatr. 138 (2001) 378-382
33. Wang W.C., et al. Granulocyte colony-stimulating factor corrects the neutropenia associated with glycogen storage disease type Ib. Leukemia 5 (1991) 347-349
34. Schroten H., et al. Granulocyte and granulocyte-macrophage colony-stimulating factors for treatment of neutropenia in glycogen storage disease type Ib. J. Pediatr. 119 (1991) 748-754
35. Visser G., et al. Consensus guidelines for management of glycogen storage disease type 1b - European Study on Glycogen Storage Disease Type 1. Eur. J. Pediatr. 161 suppl. 1 (2002) S120-S123
36. Matern D., et al. Liver transplantation for glycogen storage disease types I, III, and IV. Eur. J. Pediatr. 158 suppl. 2 (1999) S43-S48
37. Faivre L., et al. Long-term outcome of liver transplantation in patients with glycogen storage disease type Ia. J. Inherit. Metab. Dis. 22 (1999) 723-732
38. Iyer S.G., et al. Long-term results of living donor liver transplantation for glycogen storage disorders in children. Liver Transpl. 13 (2007) 848-852
39. Lerut J.P., et al. Glycogenosis storage type I diseases and evolutive adenomatosis: an indication for liver transplantation. Transpl. Int. 16 (2003) 879-884
40. Rake J.P., et al. Guidelines for management of glycogen storage disease type I - European Study on Glycogen Storage Disease Type I (ESGSD I). Eur. J. Pediatr. 161 suppl. 1 (2002) S112-S119
41. di Rocco M., et al. Hepatocellular adenoma and metabolic balance in patients with type Ia glycogen storage disease. Mol. Genet. Metab. 93 (2008) 398-402
42. Liu P.P., et al. Outcome of living donor liver transplantation for glycogen storage disease. Transplant. Proc. 35 (2003) 366-368
43. Panaro F., et al. Simultaneous liver-kidney transplantation for glycogen storage disease type IA (von Gierke's disease). Transplant. Proc. 36 (2004) 1483-1484
44. Bhattacharya N., et al. The benefits of liver transplantation in glycogenosis type Ib. J. Inherit. Metab. Dis. 27 (2004) 539-540
45. Pierre G., et al. Bone marrow transplantation in glycogen storage disease type 1b. J. Pediatr. 152 (2008) 286-288
46. Wang X., et al. Cell fusion is the principal source of bone-marrow-derived hepatocytes. Nature 422 (2003) 897-901
47. Grompe M. Liver repopulation for the treatment of metabolic diseases. J. Inherit. Metab. Dis. 24 (2001) 231-244
48. Muraca M., and Burlina A.B. Liver and liver cell transplantation for glycogen storage disease type IA. Acta Gastroenterol. Belg. 68 (2005) 469-472
49. Lee K.W., et al. Hepatocyte transplantation for glycogen storage disease type Ib. Cell Transplant. 16 (2007) 629-637
50. Lei K.J., et al. Glucose-6-phosphatase dependent substrate transport in the glycogen storage disease type-1a mouse. Nat. Genet. 13 (1996) 203-209
51. Kishnani P.S., et al. Isolation and nucleotide sequence of canine glucose-6-phosphatase mRNA: identification of mutation in puppies with glycogen storage disease type Ia. Biochem. Mol. Med. 61 (1997) 168-177
52. Zingone A., et al. Correction of glycogen storage disease type 1a in a mouse model by gene therapy. J. Biol. Chem. 275 (2000) 828-832
53. Koeberl D.D., et al. Early, sustained efficacy of adeno-associated virus vector-mediated gene therapy in glycogen storage disease type Ia. Gene Ther. 13 (2006) 1281-1289
54. Ghosh A., et al. Long-term correction of murine glycogen storage disease type Ia by recombinant adeno-associated virus-1-mediated gene transfer. Gene Ther. 13 (2006) 321-329
55. Koeberl D.D., et al. Efficacy of helper-dependent adenovirus vector-mediated gene therapy in murine glycogen storage disease type Ia. Mol. Ther. 15 (2007) 1253-1258
56. Trinh K.Y., et al. Perturbation of fuel homeostasis caused by overexpression of the glucose-6-phosphatase catalytic subunit in liver of normal rats. J. Biol. Chem. 273 (1998) 31615-31620
57. Koeberl D.D., et al. AAV vector-mediated reversal of hypoglycemia in canine and murine glycogen storage disease type Ia. Mol. Ther. 16 (2008) 665-672
58. Brix A.E., et al. Glycogen storage disease type Ia in two littermate Maltese puppies. Vet. Pathol. 32 (1995) 460-465
59. Kishnani P.S., et al. Canine model and genomic structural organization of glycogen storage disease type Ia (GSD Ia). Vet. Pathol. 38 (2001) 83-91
60. Beaty R.M., et al. Delivery of glucose-6-phosphatase in a canine model for glycogen storage disease, type Ia, with adeno-associated virus (AAV) vectors. Gene Ther. 9 (2002) 1015-1022
61. Wolfsdorf J.I., et al. Metabolic control and renal dysfunction in type I glycogen storage disease. J. Inherit. Metab. Dis. 20 (1997) 559-568